# 510(k) Summary

# k131988

# 1. Administrative

ABL90 Flex

Device Information Device Name: Common Name: Product Code: Device Classification:

Blood gases (pCO2 and pO2) and blood pH test system   
CHL, JGS, CEM, JFP, CGZ, CGA, KHP, GKR, GHS, KQI, JJY, JIX   
21 CFR 862.1120, 862.1600, 862.1345, 862.1170, 864.7425, 864.5620, 862.1145, 862.1665, 862.1150, 864.7455, 862.1660, 862.1450   
Class II, II, II, II, II, II, II, II, II, II, I (reserved), I (limitation to   
exemption per 21 CFR 862.9 (c)(9)), respectively.   
Clinical Chemistry (75) and Hematology (81)

Classification:

Classification Panel:

Purpose of submission: Introduction of a modification that consists of labeling and software changes that suppress glucose results obtained from samples with $\rho { 0 _ { 2 } }$ levels below 1OmmHg, and to suppress glucose results >270mg/dL obtained from samples with 10mmHg $< \rho 0 _ { 2 } < 2 5 \mathsf { m m H } 9 .$

Submitter Company Name: ER Number: Address:

Radiometer Medical ApS   
3002807968   
Aakandevej 21   
2700 Broenshoej   
Denmark   
$\yen 45$ 3827 3827   
$\yen 45$ 3827 2727

SEP 1 7 2013

Phone: Fax:

Application Correspondent

Name: Function: E-mail: Phone: Fax:

Gitte Juel Friis   
Regulatory Affairs   
gitte.friis@radiometer.dk   
$\pm 4 5$ 3827 3384   
$+ 4 5$ 3827 2727

# 2. Description of Device Modification

The ABL90 FLEX is a portable, automated system intended for in vitro testing of samples of whole blood for the parameters pH, $P 0 _ { 2 } , P C O _ { 2 } ,$ potassium, sodium, calcium, chloride, glucose, lactate, and co-oximetry parameters (total hemoglobin, oxygen saturation, and the hemoglobin fractions $F O _ { 2 } H b$ , FCOHb, FMetHb, FHHb and FHbF).

# 3. Intended Use

The ABL90 FLEX is a portable, automated analyzer that measures pH, blood gases, electrolytes, glucose, lactate and oximetry in heparinised whole blood. The ABL90 FLEX is intended for use by

trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient or point-of-care setting.

# 4. Indications for use

pH, pO2 and pCO2: pH, pCO2 and pO2 measurements are used in the diagnosis and treatment of life-threatening acid-base disturbances.

Potassium $( c \mathsf { K } ^ { + } )$ : potassium measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels

Sodium $( C N a ^ { + } )$ : sodium measurements are used in the diagnosis and treatment of aldosteronism, diabetes insipidus, adrenal hypertension, Addison's disease, dehydration, inappropriate antidiuretic secretion, or other diseases involving electrolyte imbalance.

Calcium $( C C a ^ { 2 + } )$ : calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.

Chloride $\left( c \mathsf { C l } ^ { - } \right)$ : chloride measurements are used in the diagnosis and treatment of electrolyte anc metabolic disorders such a cystic fibrosis and diabetic acidosis.

Glucose (cGlu): glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Lactate (cLac): The lactate measurements measure the concentration of lactate in plasma. Lactate measurements are used to evaluate the acid-base status and are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood.)

Total Hemoglobin (ctHb): total hemoglobin measurements are used to measure the hemoglobir content of whole blood for the detection of anemia.

$\bullet \mathsf { O } _ { 2 }$ : oxygen saturation, more specifically the ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus reduced hemoglobin.

$F O _ { 2 } H b$ : oxyhemoglobin as a fraction of total hemoglobin.

FCOHb: carboxyhemoglobin measurements are used to determine the carboxyhemoglobin conten of human blood as an aid in the diagnosis of carbon monoxide poisoning.

FMetHb: methemoglobin as a fraction of total hemoglobin.

FHHb: reduced hemoglobin as a fraction of total hemoglobin.

Fraction of Fetal Hemoglobin (FHbF): FHbF indicates the amount of fetal hemoglobin. FHbF is seldom used clinically.

# 5. Substantial Equivalence

The ABL90 FLEX with the modification described above is substantially equivalent in Intended Use, fundamental scientific technology, features, and characteristics to the predicate:

<table><tr><td colspan="4">Predicate: ABL90 Flex (K122729)</td></tr><tr><td></td><td>Similarities </td><td>Differences</td><td></td></tr><tr><td colspan="3" rowspan="3">Intended Use The ABL90 FLEX is a portable, automated analyzer that measures pH, blood gases, electrolytes, glucose, lactate and oximetry in heparinised whole blood. The ABL90 FLEX is intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient or point-of-care setting.</td><td>Modified caution to manual: Low pO2 levels can influence the linearity of glucose measurements, and can therefore result in falsely low glucose results. Please note that glucose performance is not specified when the p02 is less than 10 mmHg (1.33 kPa). The linearity of the glucose is dependent on</td></tr><tr><td>the oxygen tension of the sample. This dependence is due to the co-reaction of glucose and oxygen by the enzyme glucose oxidase. Low pO levels can influence the linearity of the glucose sensor. The following table outlines the glucose linearity as a function of the pO. Modified information to manual:</td></tr><tr><td>Impact of the pO2 level on Glucose linearity and specifications of the ABL90</td></tr><tr><td rowspan="5"></td><td colspan="3">FLEX analyzer</td></tr><tr><td>If the pO2 level in a</td><td colspan="2">Then cGlu linearity specifications only apply</td></tr><tr><td>sample is: &lt;10 mmHg (1.33 kPa)</td><td colspan="2">to cGlu values between: Linearity not specified. Glu is not usable.</td></tr><tr><td>10 ≤ p02 &lt; 25 mmHg (1.3 ≤ pO2 &lt; 3.3 kPa)</td><td colspan="2">0.5 - 15 mmol/L (9 - 270 mg/dL) If cGlu &gt;270 mg/dL, the linearity is not specified and the cGlu value not</td></tr><tr><td>≥25 mmHg (3.3 kPa)</td><td colspan="2">usable. 0.5 - 40 mmol/L (9 - 720 mg/dL)</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Predicate: ABL90 Flex (K122729)}$</td></tr><tr><td rowspan=1 colspan=1>Similarities    =:.    }$</td><td rowspan=1 colspan=1>-    ::        Differences</td></tr><tr><td rowspan=1 colspan=1>Electrolyte MeasurementcK+, cNa+, cCa2+, cCl by potentiometry</td><td rowspan=1 colspan=1>Software changes:Suppression of glucose results whenp02 &lt; 10 mmHgSuppression of glucose results&gt;270mg/dL when pO2 is between 10 -25mmHgMessage: &quot;Glu not usable&quot;</td></tr><tr><td rowspan=1 colspan=1>Metabolite MeasurementcGlu, cLac by amperometry</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Oximetry MeasurementctHb, sO FO2Hb, FHHb, FCOHb, FMetHb,FHbF</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Hemoglobin MeasurementSpectrophotometry</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Identical Performance Characteristics</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Two-Point liquid calibration</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Menu driven touch screen</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Software operating system Microsoft XPE</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample Introduction Aspiration</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Dimensions (length x width x depth)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>External Power Source230/120 V mains</td><td rowspan=1 colspan=1></td></tr></table>

6. Design Control Activities   

<table><tr><td rowspan=1 colspan=1>#/ Hazard3 t.2$</td><td rowspan=1 colspan=1>ValidationsandVerificationsactivitiesdescriptions</td><td rowspan=1 colspan=1>Pre- s.determinedAcceptancecriteria </td><td rowspan=1 colspan=1>Testing results summary\f}$</td><td rowspan=1 colspan=1>Meet the acceptancecriteria or not?4</td></tr><tr><td rowspan=2 colspan=1>41/Too lowGlucose result inthe upperreportable rangeobtained fromsamples withlow pO2 level48/Unacceptablebias on Glucoseresults obtainedfrom sampleswith p02 levelsabove 25 mmHg49/Too lowGlucose result inthe lower andmediumreportable rangeobtained fromsamples withlow p02level</td><td rowspan=1 colspan=1>Interferencestudy atdifferent pOzlevels and atdifferentglucose levelscovering thereportablerange of theanalyserusing freshheparinizedwhole bloodsamples.</td><td rowspan=1 colspan=1>Bias: ≤10%for glucosewhen pO2 is&gt; 10 mmHgwhencompared tothe control</td><td rowspan=1 colspan=1>6 different pO levels+ pO2 ≥90 mmHg as control7 different glucose levels3 analyzers6 tests of each sample on eachanalyzer2 runsTotal of 1512 measurementsThe results are valid under theconditions that- all glucose results aresuppressed when the pOzlevel of the sample is below10 mmHg, andall glucose results aresuppressed when pO level ofthe sample is between 10mmHg and 25 mmHg and theglucose level is above 270mg/dLall acceptance criteria are met:Bias &lt; 10%</td><td rowspan=1 colspan=1>Passed- The acceptance criterion ismet under the conditionsthat all glucose results aresuppressed when the pOzlevel of the sample isbelow 10 mmHg, andall glucose results aresuppressed when pO levelof the sample is between10 mmHg and 25 mmHgand the glucose level isabove 270 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Precisionstudy atdifferent pO2levels and atdifferentglucose levelsrepresentingclinicaldecisionpoints at low,medium andhigh glucose.</td><td rowspan=1 colspan=1>CV%: ≤10%</td><td rowspan=1 colspan=1>20 days3 different pO levels3 different glucose levels2 tests of each sample eachday2 runsTotal of 2160 measurementsThe results are valid under theconditions thatall glucose results aresuppressed when the pO2level of the sample is below10 mmHg, andall glucose results aresuppressed when pO level ofthe sample is between 10mmHg and 25 mmHg and theglucose level is above 270mg/dLall acceptance criteria are met:CV% ≤ 10%</td><td rowspan=1 colspan=1>PassedThe acceptance criterion ismet under the conditionsthat all glucose results aresuppressed when the pOzlevel of the sample isbelow 10 mmHg, andall glucose results aresuppressed when pO2 levelof the sample is between10 mmHg and 25 mmHgand the glucose level isabove 270 mg/dL</td></tr></table>

# 5. Performance Characteristics

# Precision

Precision was evaluated according to CLSI guideline "Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second Edition", EP05-A2.

The study was conducted as a 20 day precision study using serum pool sample of glucose.   
Three levels of glucose have been analyzed in 2 runs per day with 2 replicates for each level.

<table><tr><td rowspan=1 colspan=7>$ra$                              F. s   -:Results of Precision Study:             im$}$          T  2              -          :. . .--3. :H</td></tr><tr><td rowspan=2 colspan=1>- :.cGlu level</td><td rowspan=2 colspan=1>2i  4 4pO level</td><td rowspan=1 colspan=3>74    e Tndmg/dLi$fa$</td><td rowspan=1 colspan=2>-•</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>sr</td><td rowspan=1 colspan=1>ST</td><td rowspan=1 colspan=1>CV%E</td><td rowspan=1 colspan=1>2     :n: ,i</td></tr><tr><td rowspan=3 colspan=1>Glu Low       λ17.8 ± 2.5mg/dL$ra1 }$</td><td rowspan=1 colspan=1>10 mmHg</td><td rowspan=1 colspan=1>17.9</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1> 30 mmHg</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>r::&quot;&gt;90 mmHg</td><td rowspan=1 colspan=1>18.1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=3 colspan=1>Glu Mid98.7 ±9       fmg/dL</td><td rowspan=1 colspan=1>2 10 mmHg</td><td rowspan=1 colspan=1>101.7</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>30 mmHg 2,&#x27;*</td><td rowspan=1 colspan=1>101.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>J &gt;90 mmHg3</td><td rowspan=1 colspan=1>101.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=3 colspan=1>Glu High270 ± 6 mg/dL∴:</td><td rowspan=1 colspan=1>10 mmHg</td><td rowspan=1 colspan=1>254.1</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>30 mmHg  &quot;52</td><td rowspan=1 colspan=1>262.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>&gt;90mmHg</td><td rowspan=1 colspan=1>271.9</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>240</td></tr></table>

# Method Comparison

Method comparison study versus a comparative analyzer (ABL735) has been conducted according to NCCLS guideline "Method Comparison and Bias Estimation Using Patient Samples", EP09-A2.

This study was an in-house method comparison using untreated donor samples in combination with spiked donor blood where necessary. A total of 52 different donors are used in data mining and approximately 500 samples are measured

Linear regression of the pooled data gives a slope of 0.9206, intercept of 0.084 and an ${ \mathbb R } ^ { 2 } \geq$ 0.95; fulfiling the requirements to slope (0.9 - 1.1), intercept (0) and correlation coefficient $( \geq 0 . 9 5 )$ EPY

![](images/1ea73755a76cb4daf1d520dd8379076cfff4e04f11f0f4f60738a32f66abde91.jpg)

# Interference

Interference study has been conducted according to CLSI guideline "Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition", EP07-A2.

This study evaluates the $\rho { \mathsf { O } } _ { 2 }$ tension in blood samples as an interfering substance to the glucose measurement.

<table><tr><td rowspan=1 colspan=8>Results of Interference Study                                                   52.</td></tr><tr><td rowspan=2 colspan=2>CV%(XTEST*;2h.XCONTROL</td><td rowspan=1 colspan=6>*                          i                                   61         &quot;5¥.* :-; 1*iitspO2[mmHg]</td></tr><tr><td rowspan=1 colspan=1>-10 “tp7    γ′*¤4</td><td rowspan=1 colspan=1>,t.    515</td><td rowspan=1 colspan=1>4-       320* M</td><td rowspan=1 colspan=1>,&quot;  25   &quot;I8</td><td rowspan=1 colspan=1>2. 50</td><td rowspan=1 colspan=1>T.:       2:4.*80vl5· ; :</td></tr><tr><td rowspan=7 colspan=1>/w] </td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.2%</td></tr><tr><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.4%</td></tr><tr><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=1 colspan=1>270  ..</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>13.6%</td><td rowspan=1 colspan=1>9.3%</td><td rowspan=1 colspan=1>7.1%</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.7%</td></tr></table>

# 6. Performance Data

The performance data submitted in the original submission (ko92686) still apply.

# 7. Conclusion

The ABL90 FLEX with the modification described above is substantially equivalent in Intended Use, fundamental scientific technology, features, and characteristics to the predicate ABL90 Flex (K122729).

# September 17, 2013

Radiometer Medical ApS   
C/O Gitte Juel Friis   
Akandevej 21   
2700 Bronshoj   
DENMARK

Re: K131988 Trade/Device Name: ABL90 Flex Analyzer Regulation Number: 21 CFR 862.1120 Regulation Name: Blood gases (PCO2, PO2) and blood pH test system Regulatory Class: II Product Code: CHL JGS, CEM, JFP, CGZ, CGA, KHP, GKR, GHS, KQI, JJY, JIX Dated: June 24, 2013 Received: June 28, 2013

Dear Mr. Friis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm! 15809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/defauit.htm.

Sincerely yours,

# Carol GBenson -S for

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

510(k) Number (if known): k131988

Device Name: ABL90 Flex Analyzer

Indication For Use:

# Intended Use:

The ABL90 FLEX analyzer is a portable, automated analyzer that measures $\mathsf { p H }$ , blood gases, electrolytes, glucose, lactate, and oximetry in heparinised whole blood. The ABL90 FLEX analyzer is intended for use by trained technologists, nurses, physicians and therapists. It is intended for use in a laboratory environment, near patient or point-ofcare setting. These tests are only performed under a physician's order.

# Indications for use:

pH, $\pmb { p } \pmb { 0 } \pmb { 2 }$ and $p { \bf C O 2 : } \mathrm { p H } , p { \bf C O 2 }$ and $p 0 2$ measurements are used in the diagnosis and treatment of life-threatening acid-base disturbances.

Potassium $( c \mathbf { K } ^ { + } )$ : potassium measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.

Sodium $( c \mathbf { N a } ^ { + } )$ : sodium measurements are used in the diagnosis and treatment of aldosteronism, diabetes insipidus, adrenal hypertension, Addison's disease, dehydration,inappropriate antidiuretic secretion, or other diseases involving electrolyte imbalance.

Calcium $( \mathbf { c } \mathbf { C _ { a } } ^ { + + } )$ : calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany.

Prescription Use__ X And/Or Over the Counter Use (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR) Yung WFChan -S

Chloride (cCr ): chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such a cystic fibrosis and diabetic acidosis.

Glucose (cGlu): glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Lactate (cLac): The lactate measurements measure the concentration of lactate in plasma. Lactate measurements are used to evaluate the acid-base status and are used in the diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood.)

Total Hemoglobin (ctHb): total hemoglobin measurements are used to measure the hemoglobin content of whole blood for the detection of anemia.

$\pmb { \mathscr { s o } _ { 2 } }$ : oxygen saturation, more specifically the ratio between the concentration of oxyhemoglobin and oxyhemoglobin plus reduced hemoglobin.

$F O _ { 2 } H _ { 2 }$ : oxyhemoglobin as a fraction of total hemoglobin.

FcoHb: carboxyhemoglobin measurements are used to determine the carboxyhemoglobin content of human blood as an aid in the diagnosis of carbon monoxide poisoning.

FMetHb: methemoglobin as a fraction of total hemoglobin.

FHHb: reduced hemoglobin as a fraction of total hemoglobin.

Fraction of Fetal Hemoglobin (FHbF): FHbF indicates the amount of fetal hemoglobin. FHbF is seldom used clinically.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)